EuropaBio

EuropaBio, formally known as the European Association for Bioindustries, is a Brussels-based industry association representing biotechnology businesses and related national organizations at the European and international levels. It was initiated in 1996 to provide a collective voice for the biotechnology sector in European policy debates, particularly in relation to legislation, market access, innovation policy, and the social and ethical questions surrounding biotechnology. The association's membership spans two broad areas. Red, or healthcare, biotechnology covers the use of biological science in medicines, therapies, diagnostics, and related healthcare applications. White, or industrial, biotechnology applies biological processes to manufacturing, bioenergy, biofuels, biomaterials, and other industrial purposes. This dual-sector structure allows EuropaBio to present biotechnology as both a healthcare platform and a component of Europe's wider industrial and environmental transition. EuropaBio's principal institutional audience is the European Union. The organization engages with the European Parliament, the European Commission, the Council of Ministers, and other policy stakeholders in an effort to shape legislation and regulatory conditions affecting biotechnology companies. Its stated policy objectives include supporting an innovative and dynamic biotechnology industry, promoting open and competitive markets, reducing barriers that could disadvantage European companies compared with businesses in other regions, and encouraging informed dialogue about biotechnology's economic, social, ethical, and environmental implications. The association also advocates what it describes as socially responsible use of biotechnology. Its activities therefore combine industry representation with public-policy communication: it seeks to explain potential benefits of biotechnology while arguing that regulation should be proportionate, science-informed, and compatible with innovation. Because biotechnology businesses operate across national borders, EuropaBio also represents members in transatlantic and global forums, even though European Union policy remains its primary focus. EuropaBio is governed by a board of management composed of representatives from member companies. Sectoral councils support the board in the healthcare and industrial biotechnology fields, while a National Associations Council gives national biotechnology organizations a formal channel within the association. Expert representatives from corporate members and national associations contribute to working groups addressing specific policy and technical issues. According to information cited for 2021, EuropaBio represented 79 corporate and associate members and BioRegions, together with 17 national biotechnology associations that collectively represented more than 1,800 biotechnology small and medium-sized enterprises. The association's leadership has included Director General Dr. Claire Skentelbery, who has held that role since November 2020, and Dr. Sarah Reisinger of dsm-firmenich, identified as chair of the board from 2023. EuropaBio is not a product brand or a publicly listed company; its principal offerings are advocacy, policy engagement, industry coordination, and communications on behalf of the biotechnology sector.

EuropaBio was initiated in 1996 as a European-level organization for the biotechnology industry. Its formation reflected the increasingly cross-border character of biotechnology and the need for companies and national sector organizations to engage with European institutions collectively rather than relying only on country-by-country representation. From its Brussels base, EuropaBio developed an advocacy model centered on dialogue with the European Parliament, European Commission, and Council of Ministers. The association's remit has covered legislation and regulation affecting biotechnology enterprises, the competitiveness of European companies, innovation policy, and public discussion of biotechnology's social and ethical dimensions. Rather than operating as a manufacturer or research company, it has functioned as a representative and coordinating body for the sector. The organization has represented two principal segments. Healthcare, or red biotechnology, concerns biological approaches to medicines and therapies. Industrial, or white biotechnology, concerns the use of biological processes in manufacturing, alternative energy, biofuels, and biomaterials. This structure gives EuropaBio a broad mandate spanning healthcare innovation and industrial applications of biotechnology. Its public policy objectives include creating conditions for an innovative and dynamic biotechnology industry in Europe, supporting open markets, reducing barriers to international competitiveness, and encouraging transparent discussion with stakeholders. EuropaBio also presents socially responsible use as a core principle, arguing that biotechnology's potential should be developed in ways that benefit people and the environment. The association's work has included engagement on politically sensitive biotechnology questions. In 2011, reporting by The Guardian described an EuropaBio effort to recruit high-profile ambassadors for a campaign concerning genetically modified food. The episode illustrated the association's role in public communication as well as its advocacy role, while also placing industry-backed messaging within the wider controversy surrounding genetically modified foods in Europe. By 2020, Dr. Claire Skentelbery had become Director General, a position she held from November of that year. The association's governance also included a board of management drawn from industry members, sectoral councils for healthcare and industrial biotechnology, a National Associations Council, and expert working groups. In 2023, Dr. Sarah Reisinger of dsm-firmenich was identified as chair of the board. Information cited for 2021 described a network of 79 corporate and associate members and BioRegions, alongside 17 national biotechnology associations. Those national bodies were in turn described as representing more than 1,800 biotechnology small and medium-sized enterprises. EuropaBio's primary geographic focus remains the European Union, but its representation extends to transatlantic and worldwide forums because biotechnology markets, supply chains, research, and regulation are global in scope.

1. 2023Sarah Reisinger identified as board chair

   Dr. Sarah Reisinger, representing dsm-firmenich, was identified as chair of EuropaBio's board of management.

   Source
2. 2021Membership network reported

   EuropaBio was reported as representing 79 corporate and associate members and BioRegions, plus 17 national biotechnology associations representing more than 1,800 biotechnology SMEs.

   Source
3. 2020Claire Skentelbery becomes Director General

   Dr. Claire Skentelbery became EuropaBio's Director General in November 2020.

   Source
4. 2011Genetically modified food ambassador campaign reported

   The Guardian reported on EuropaBio's attempt to recruit prominent ambassadors for a campaign intended to influence European perceptions of genetically modified food.

   Source
5. 1996EuropaBio is initiated

   The European Association for Bioindustries is initiated to represent biotechnology interests at the European level and engage with European legislation and policy.

   Source

A pan-European biotechnology industry association and policy advocate representing healthcare and industrial biotechnology interests.

Product categories. Industry advocacy · European biotechnology policy representation · Regulatory and legislative engagement · Stakeholder dialogue · Biotechnology communications and public affairs · Member working groups and sector councils

• 2011Genetically modified food ambassadors programme

  Europe

  EuropaBio pursued a public-affairs campaign designed to recruit recognizable figures as ambassadors for genetically modified food. The stated purpose was to help transform European perceptions of the technology and communicate arguments favorable to its use.

  Outcome. The campaign and draft outreach material were reported by The Guardian. The available reference material does not establish a measurable change in public opinion or a definitive organizational outcome.

  Source

• 2011Use high-profile ambassadors in genetically modified food communicationsStrategy

  European debate over genetically modified food included substantial public opposition and controversy. EuropaBio sought a more prominent public-facing communications approach.

  What changed. The association explored recruiting well-known figures to act as ambassadors for a campaign supporting a more favorable understanding of genetically modified food.

  Aftermath. The effort was covered by The Guardian through reporting on the proposed ambassadors and related correspondence. No verified financial result or quantified communications impact is provided in the available sources.

  Source

• 2011EuropaBio promoted a European campaign on genetically modified food

  EuropaBio sought to recruit prominent public figures as ambassadors for a communications effort intended to change perceptions of genetically modified food in Europe. The initiative was reported in connection with documents and correspondence concerning potential ambassadors.

  CampaignOther
  Source

1. EuropaBio
2. Transforming Europe’s position on GM food: ambassadors programme executive summary